Evaluation of Rate Adaptive Pacing on Chronotropic Response in Preserved Ejection Fraction HF

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2017-07-01

Study Completion Date

2018-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RESPOND-HF is a prospective, multi-center, non-significant risk pilot study with cross-over design. The purpose of the study is to investigate if rate adaptive pacing has the potential to provide benefit to HF patients with preserved ejection fraction, referred to as HFpEF patients. Findings from this pilot study may be used to guide subsequent efforts to design and conduct a prospective, randomized, multi-center pivotal trial powered to show improvement in patient outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy Study of Pacemakers to Treat Slow Heart Rate in Patients With Heart Failure

NCT02145351

Heart Failure With a Preserved Ejection Fraction Heart Failure, Diastolic Chronotropic Incompetence

COMPLETED NA

Physiologic Accelerated Pacing as a Treatment in Patients With Heart Failure With Preserved Ejection Fraction

NCT04546555

Heart Failure, Diastolic

COMPLETED NA

REmodeling the Left Ventricle With Atrial Modulated Pacing

NCT03210402

Heart Failure

COMPLETED NA

PROSPECT: Predictors of Response to Cardiac Re-Synchronization Therapy

NCT00253357

Heart Failure Congestive Heart Failure Cardiomyopathy

COMPLETED

Cardiac Resynchronisation Therapy Versus Rate-responsive Pacing in Heart Failure With Preserved Ejection Fraction

NCT03338374

Diastolic Heart Failure

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The RESPOND-HF is a prospective, multi-center, investigational, pilot study with cross-over design. Patients with existing pacemakers who have been diagnosed with HFpEF and meet study inclusion/exclusion criteria will be included in the study.

The study is expected to be conducted at up to 5 centers in the United States and up to 300 patients will be consented to enroll up to 100 qualifying patients . Up to 60 patients meeting chronotropic incompetence (CI) criterion will be enrolled. The study will be conducted in subjects who have previously (≥ 30 days) been implanted with Medtronic, dual chamber pacemaker (IPG) device with rate adaptive pacing (RAP) feature. Additionally, up to 40 patients who do not meet CI criterion will be enrolled to collect ambulatory activity and heart rate data using AVIVO/SEEQ patch. These patients will be followed for only 1 week. It is estimated that subject enrollment will take approximately 12 to 18 months, with a study follow-up of 18 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure With Preserved Ejection Fraction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

To assess whether rate adaptive pacing provides benefit to HFpEF patients, a pool of up to 60 qualifying subjects with pre-existing pacemaker and established diagnosis of HFpEF who demonstrate chronotropic incompetence (CI) with RAP turned off will be enrolled.

Subjects who meet CI criterion during Visit 2 will be randomized. Subjects' principal investigator and study team will be blinded to the randomization assignment. However clinical site personnel performing the device programming will not be blinded. Site personnel performing the CPET and 6-min hall walk assessments will be blinded to the randomization assignment.

Crossover of study subjects will occur during Visit 3, which will occur 12 weeks after subject enrollment. Subjects who were randomized with RAP ON first will have the device programmed to RAP OFF and conversely, subjects who were randomized to RAP OFF first will have the device programmed to RAP ON.

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Subjects' principal investigator and study team will be blinded to the randomization assignment. However clinical site personnel performing the device programming will not be blinded. Site personnel performing the CPET and 6-min hall walk assessments will be blinded to the randomization assignment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Rate Adaptive Pacing ON

The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be programmed to level 4 (More Active Lifestyle) with ADL rate of 95 bpm or higher, and Upper sensor rate that is subject's age predicted maximum heart rate. The age predicted maximum heart rate (APMHR) will be computed as: APHMR = 220 - age

Group Type ACTIVE_COMPARATOR

Rate Adaptive Pacing

Intervention Type DEVICE

Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.

Rate Adaptive Pacing OFF

The Rate Adaptive Pacing (RAP) feature in the Medtronic implantable pulse generator (IPG) will be turned off for this arm of the study.

Group Type ACTIVE_COMPARATOR

Rate Adaptive Pacing

Intervention Type DEVICE

Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rate Adaptive Pacing

Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years or legal age to provide informed consent
* Willing and be able to provide informed consent
* Previous clinical diagnosis of HF and exhibits HF signs and symptoms consistent with NYHA II or III (or class B or C)
* Chronic Rx for heart failure with loop diuretic or a mineralocorticoid receptor antagonist (MRA)
* LVEF ≥ 45% within previous 12 months. Acceptable methods include echo, ventriculogram (angiography or nuclear), nuclear stress test. If patient has a prior history of significant left ventricular systolic dysfunction defined as EF \< 0.40, patient must have a HF event within previous 12 months defined as:

* Hospitalization for decompensated HF
* Unscheduled treatment for HF with intravenous loop diuretic or hemofiltration
* On stable HF medical therapy for previous 30 days. Dose changes of ACEI / ARB and beta blockers of less than 50% increase or decrease are acceptable for stability
* Treadmill exercise time using modified Naughton protocol of greater than 3 min and less than 15 min for men and 14 for women
* Medtronic dual chamber pacemaker implanted for ≥ 30 days
* Sinus rhythm at rest

Exclusion Criteria

* Women who are pregnant or plan to become pregnant
* Life expectancy less than 1 year
* Enrollment in any concurrent study that could potentially be confounding
* Orthopedic, neuromuscular or any other condition limiting exercise testing
* Unstable angina or MI or have undergone CABG/PTCA within previous 60 days
* A candidate for CABG/PTCA at the time of informed consent
* Use of inotrope therapy on a regular basis (e.g. daily, weekly etc.)
* Severe and/or poorly controlled major active comorbidity, including (but not limited to):

* Diabetes: Hb1AC \> 9.5
* Severe COPD: e.g. end stage emphysema managed using 2 or more inhalers and/or using home oxygen
* Severe pulmonary disease limiting functional capacity
* Hypertension: SBP \> 160 mmHg at time of screening
* Cancer: Ongoing therapy or therapy within previous 3 months
* Severe valvular disease
* Renal impairment with serum creatinine \> 3 mg/dL
* Anemia with hemoglobin \< 8 g/dL or major bleeding event within the past 60 days
* Primary diagnosis of pulmonary arterial hypertension with ongoing severe pulmonary hypertension and treatment
* Known familial hypertrophic cardiomyopathy or hypertrophic obstructive cardiomyopathy
* Known restrictive cardiomyopathy or systemic illness known to be associated with infiltrative myocardial disease (e.g. amyloidosis, sarcoidosis, hemochromatosis)
* Pericardial restriction or hemodynamically significant pericardial effusion
* Patients expected to undergo device or lead replacement within study follow-up duration
* Allergies to hydrogel in SEEQ/AVIVO patch
* Patients who are expected to be ventricular paced over 40% of the time
* Long standing persistent AF Or Ongoing episode of persistent AF

Eligible Sex

ALL

Accepts Healthy Volunteers

No